RedHill Biopharma’s Opaganib Demonstrates Complete Inhibition of SARS-CoV-2

Opaganib blocks SARS-Cov-2 virus replication Opaganib completely inhibited SARS-CoV-2 viral replication as measured after three days incubation in an in vitro model of human bronchial tissue, comparing favorably with remdesivir, the positive control in the study — Opaganib is uniquely positioned as an orally-administered potential COVID-19 treatment combining potent antiviral and anti-inflammatory mechanisms of action, […]

Read More